Drug & intervention

brigatinib

RxCUI 1921217

Clinical trials28
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

28 shown
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung CancerNCT05100069 · 2021-11-01
RECRUITING
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)NCT06522360 · 2024-12-11
WITHDRAWN
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerNCT06532149 · 2024-08-05
UNKNOWN
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung CancerNCT05718297 · 2024-06-07
WITHDRAWN
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)NCT05721950 · 2024-01-17
ACTIVE_NOT_RECRUITING
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.NCT05834348 · 2023-06-23
COMPLETED
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.NCT05361564 · 2022-06-01
UNKNOWN
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.NCT04647110 · 2020-12-14
COMPLETED
Brigatinib Before Brain Irradiation Trial (B3i Trial)NCT04634110 · 2020-11-17
TERMINATED
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07
UNKNOWN
Brigatinib in ALK-positive NSCLC Identified Via Blood-based AssaysNCT04074993 · 2020-05-15
UNKNOWN
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsNCT04223596 · 2020-05-04
ACTIVE_NOT_RECRUITING
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep PhenotypingNCT04318938 · 2020-03-30
COMPLETED
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLCNCT04227028 · 2020-03-09
ACTIVE_NOT_RECRUITING
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung CancerNCT04005144 · 2020-02-25
TERMINATED
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNCT03737994 · 2019-07-25
TERMINATED
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid TumorsNCT03420742 · 2019-06-26
COMPLETED
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerNCT03596866 · 2019-04-19
COMPLETED
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid CancersNCT03868423 · 2019-03-20
WITHDRAWN
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibNCT03535740 · 2019-01-31
COMPLETED
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerNCT03707938 · 2018-12-18
ACTIVE_NOT_RECRUITING
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) InhibitorsNCT03546894 · 2018-07-23
COMPLETED
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)NCT03410108 · 2018-01-29
COMPLETED
Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsNCT02706626 · 2017-03-09
TERMINATED
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsNCT02737501 · 2016-05-26
COMPLETED
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibNCT02094573 · 2014-06-04
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)NCT01449461 · 2011-09-20
COMPLETED
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerNCT02784158
NO_LONGER_AVAILABLE

Conditions being studied

Non-small Cell Lung Cancer6Lung Cancer4Stage IV Lung Cancer AJCC v83Stage IVA Lung Cancer AJCC v83Stage IVB Lung Cancer AJCC v83Advanced Malignancies2ALK Gene Rearrangement2ALK-positive Advanced NSCLC2Carcinoma2Carcinoma, Non-Small-Cell Lung2Lung Non-Small Cell Carcinoma2Non Small Cell Lung Cancer2Non-small Cell Lung Cancer (NSCLC)2NSCLC2NSCLC Stage IV2Recurrent Lung Non-Small Cell Carcinoma2Advanced Lung Carcinoma1Advanced Malignant Neoplasm1ALK Fusion Protein Expression1ALK Gene Amplification1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.